RGLS - Regulus Therapeutics Inc.
IEX Last Trade
1.54
-0.005 -0.325%
Share volume: 4,005
Last Updated: Fri 27 Dec 2024 08:30:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.54
0.00
-0.32%
Fundamental analysis
33%
Profitability
43%
Dept financing
21%
Liquidity
37%
Performance
25%
Performance
5 Days
4.58%
1 Month
-2.44%
3 Months
-0.62%
6 Months
-20.79%
1 Year
22.14%
2 Year
36.75%
Key data
Stock price
$1.54
DAY RANGE
$1.46 - $1.56
52 WEEK RANGE
$1.22 - $3.79
52 WEEK CHANGE
$25.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Joseph P. Hagan
Region: US
Website: regulusrx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: regulusrx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Regulus Therapeutics Inc. engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Recent news